Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum

About the Cover

December 07, 2017; Volume 12,Issue 12

Looking for COVID information? All ASN Journal COVID articles are available in the COVID collection. All articles are free.​

Cover image

Cover image expansion

On the Cover

What’s the diagnosis?

A 72 year-old woman with a history of end-stage kidney disease secondary to hypertensive nephrosclerosis status post living donor kidney transplant six months prior presented for evaluation of skin lesions. She reported the appearance of tender, erythematous skin lesions on her bilateral upper and lower extremities and face one week prior to presentation, with new lesions appearing daily. She denied other symptoms. She underwent a skin biopsy which demonstrated lobular panniculitis with mixed inflammatory infiltrate; stains for fungi and mycobacteria were negative. Fungal culture of the biopsied tissue grew mold, identified by DNA sequencing as Blastomyces dermatitidis.

She was admitted for evaluation and treatment. A magnetic resonance image (MRI) of the brain revealed multiple new intraparenchymal, leptomeningeal, and facial subcutaneous enhancing foci suspicious for blastomycosis. A computer to mography image of the chest showed a centrally necrotic hilar lymph node and a few scattered pulmonary nodules. She was initiated on treatment with intravenous liposomal amphotericin and had improvement in her skin lesions within three days. Follow-up brain MRI two weeks later showed decreased size and associat ede dema of the enhancing brain lesions. She was transitioned to oral voriconazole but was unable to achieve therapeutic levels and is now on oral posaconazole for a planned 12 month course, and is clinically stable.

Learning objectives:

Blastomycosis is caused by an endemic fungus found in decomposing wood and leaves primarily in the Ohio and Mississippi River Valleys and the Great Lakes region. Infection usually follows inhalations of spores and is typically localized to the lungs but approximately 30% of those infected will develop extra-pulmonary manifestations (1). Disseminated infection is more common in immunosuppressed populations, such as solid organ transplant recipients and HIV-infected individuals. Early recognition and treatment is essential to achieve best outcomes.

Lipid formulations of amphotericin B are the recommended treatment for blastomycosis in immunosuppressed patients. A 1-2 week course, or until clinical improvement is noted, is recommended, with step down to itraconazole therapy for 12 months thereafter (2). When central nervous system disease is present, alonger 4-6 week course of amphotericin B lipid formulation is recommended, followed by an oral azole for at least 12 months (2). The optimal azole for treatment remains debatable; voriconazole and posaconazole have excellent CNS penetration and have been used with success.

Image descriptions:

1. Erythematous papules and plaques, some with overlying erosion and crust, located on the cheek

2. Magnetic resonance image of brain showing multiple intraparenchymal, left frontal leptomeningeal and facial subcutaneous softtissue enhancing foci suspicious for infectious blastomycosis

3. Fungal culture demonstrating mold with septate hyphae with round conidia at the apex of short and long conidiophores in a“lollipoplike” appearance, consistent with Blastomyces dermatitidis

References:

1. Crampton TL, Light RB, Berg GM, Meyers MP, Schroeder GC, Hershfield ES, Embil JM. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis 34: 1310–1316, 2002

2. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA. Clinical practice guidelines for themanagement of blastomycosis: 2008 update by the Infectious Disease Society of America. Clin Infect Dis 46: 1801–1812, 2008

(Images and text provided by Alden Michael Doyle, MD and Jessica Lewis, MD, University of Virginia, Charlottesville, Virginia)

Back to top
PreviousNext

In this issue

Clinical Journal of the American Society of Nephrology: 12 (12)
Clinical Journal of the American Society of Nephrology
Vol. 12, Issue 12
December 07, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Sign up for alerts
View Selected Citations (0)

Jump to

  • Editorials
  • Original Articles
    • Chronic Kidney Disease
    • Clinical Nephrology
    • Cystic Kidney Disease
    • Diabetes and the Kidney
    • Maintenance Dialysis
    • Transplantation
  • Glomerular Diseases: Update for the Clinician
  • Kidney Case Conference: How I Treat
  • Perspectives
  • Feature
  • Most Read
Loading
  • Drug-Induced Acute Kidney Injury
  • Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
  • The Intensivist's Perspective of Shock, Volume Management, and Hemodynamic Monitoring
  • Classification of Uremic Toxins and Their Role in Kidney Failure
  • Recurrent Glomerular Disease after Kidney Transplantation
More...

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire